Ariad Pharmaceuticals (ARIA) Moves Higher after FDA Node for Iclusig
Tweet
Share
E-mailGet Alerts ARIA Hot Sheet
Join SI Premium – FREE
Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA) moves higher on news the FDA approved Iclusig to treat two rare types leukemia.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Exchange Traded Concepts and ARIAM Global launch ARIA an Actively Managed ETF Led by a Portfolio Manager with a Ph.D. in AI and Computer Science
- Berkshire adds significantly to Alphabet position, starts small position in DR Horton
- Outlook Therapeutics posts Q3 loss, eyes U.S. LYTENAVA launch by end of 2026
Create E-mail Alert Related Categories
FDA, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
